Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genor Biopharma Holdings's enterprise value is €60.51 Mil.
Genor Biopharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €6.43 Mil. Therefore, Genor Biopharma Holdings's EV-to-EBITDA for today is 9.41.
The historical rank and industry rank for Genor Biopharma Holdings's EV-to-EBITDA or its related term are showing as below:
FRA:67N0'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -58.22 Med: 0.79 Max: 17.51
Current: 9.41
During the past 7 years, the highest EV-to-EBITDA of Genor Biopharma Holdings was 17.51. The lowest was -58.22. And the median was 0.79.
FRA:67N0's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 13.725
vs FRA:67N0: 9.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genor Biopharma Holdings's PE Ratio (TTM) for today is calculated as:
Genor Biopharma Holdings's share price for today is €0.336.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:67N0 vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Genor Biopharma Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genor Biopharma Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genor Biopharma Holdings's EV-to-EBITDA falls into.
Genor Biopharma Holdings's current Enterprise Value is €60.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was €6.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genor Biopharma Holdings (FRA:67N0) has a EV-to-EBITDA of 9.41 as of Sep. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genor Biopharma Holdings. This is 1091% above median its historical median of 0.79.
Is Genor Biopharma Holdings' EV-to-EBITDA too high?
Genor Biopharma Holdings' current EV-to-EBITDA of 9.41 is 1091% above median its 10-year median of 0.79. The Biotechnology industry median EV-to-EBITDA is 13.73. Genor Biopharma Holdings' value of 9.41 is 31.4% below this industry median. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' EV-to-EBITDA compare to VRTX and REGN?
Genor Biopharma Holdings' EV-to-EBITDA of 9.41 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 13.73. Genor Biopharma Holdings' value of 9.41 is 31.4% below this benchmark. While the company's 10-year median is 0.79 vs. the industry median of 13.73, Genor Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.73, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genor Biopharma Holdings's current EV-to-EBITDA of 9.41 is 31.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genor Biopharma Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current EV-to-EBITDA is 9.41, which is 1091% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current EV-to-EBITDA of 9.41. The current EV-to-EBITDA is 9.41, which is 1091% above median its 10-year median of 0.79 and 31.4% below the Biotechnology industry median of 13.73. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current EV-to-EBITDA is 9.41 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score
Get the complete analysis for FRA:67N0
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:67N0 has been successfully added to your 
